Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

Costimulatory blockade-mediated lung allograft acceptance is abrogated by overexpression of Bcl-2 in the recipient.

Okazaki M, Sugimoto S, Lai J, Kornfeld CG, Hotchkiss RS, Richardson SB, Li W, Kreisel FH, Huang HJ, Patterson GA, Krupnick AS, Gelman AE, Kreisel D.

Transplant Proc. 2009 Jan-Feb;41(1):385-7. doi: 10.1016/j.transproceed.2008.10.068.

PMID:
19249562
2.

Aggressive skin allograft rejection in CD28-/- mice independent of the CD40/CD40L costimulatory pathway.

Ha J, Bingaman AW, Durham MM, Pearson TC, Larsen CP.

Transpl Immunol. 2001 Oct;9(1):13-7.

PMID:
11680567
3.

Analysis of the CD40 and CD28 pathways on alloimmune responses by CD4+ T cells in vivo.

Bingaman AW, Ha J, Durham MM, Waitze SY, Tucker-Burden C, Cowan SR, Pearson TC, Larsen CP.

Transplantation. 2001 Oct 15;72(7):1286-92.

PMID:
11602857
4.

New insights in CD28-independent allograft rejection.

Habicht A, Najafian N, Yagita H, Sayegh MH, Clarkson MR.

Am J Transplant. 2007 Aug;7(8):1917-26.

6.
7.

Modulation of costimulation by CD28 and CD154 alters the kinetics and cellular characteristics of corneal allograft rejection.

Ardjomand N, McAlister JC, Rogers NJ, Tan PH, George AJ, Larkin DF.

Invest Ophthalmol Vis Sci. 2003 Sep;44(9):3899-905.

PMID:
12939307
8.

Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection.

Hancock WW, Sayegh MH, Zheng XG, Peach R, Linsley PS, Turka LA.

Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):13967-72.

9.

Cutting edge: blockade of the CD28/B7 costimulatory pathway inhibits intestinal allograft rejection mediated by CD4+ but not CD8+ T cells.

Newell KA, He G, Guo Z, Kim O, Szot GL, Rulifson I, Zhou P, Hart J, Thistlethwaite JR, Bluestone JA.

J Immunol. 1999 Sep 1;163(5):2358-62.

11.
12.

Peripheral deletion after bone marrow transplantation with costimulatory blockade has features of both activation-induced cell death and passive cell death.

Wekerle T, Kurtz J, Sayegh M, Ito H, Wells A, Bensinger S, Shaffer J, Turka L, Sykes M.

J Immunol. 2001 Feb 15;166(4):2311-6.

13.

Induction of hyperacute rejection of skin allografts by CD8+ lymphocytes.

Yoshimura R, Chargui J, Aitouche A, Veyron P, Touraine JL.

Transplantation. 2000 Apr 15;69(7):1452-7.

PMID:
10798770
14.

CD4+ T lymphocytes are not necessary for the acute rejection of vascularized mouse lung transplants.

Gelman AE, Okazaki M, Lai J, Kornfeld CG, Kreisel FH, Richardson SB, Sugimoto S, Tietjens JR, Patterson GA, Krupnick AS, Kreisel D.

J Immunol. 2008 Apr 1;180(7):4754-62.

15.

CD4 T cell-mediated rejection of cardiac allografts in B cell-deficient mice.

Nozaki T, Rosenblum JM, Ishii D, Tanabe K, Fairchild RL.

J Immunol. 2008 Oct 15;181(8):5257-63.

16.

Activation of alloreactive CD8+ T cells operates via CD4-dependent and CD4-independent mechanisms and is CD154 blockade sensitive.

Zhai Y, Meng L, Busuttil RW, Sayegh MH, Kupiec-Weglinski JW.

J Immunol. 2003 Mar 15;170(6):3024-8.

17.

The role of the IL-2 pathway in costimulation blockade-resistant rejection of allografts.

Jones TR, Ha J, Williams MA, Adams AB, Durham MM, Rees PA, Cowan SR, Pearson TC, Larsen CP.

J Immunol. 2002 Feb 1;168(3):1123-30.

18.

Coronary arteriosclerosis after T-cell-mediated injury in transplanted mouse hearts: role of interferon-gamma.

Nagano H, Libby P, Taylor MK, Hasegawa S, Stinn JL, Becker G, Tilney NL, Mitchell RN.

Am J Pathol. 1998 May;152(5):1187-97.

19.

Antibody-mediated rejection of cardiac allografts in CCR5-deficient recipients.

Nozaki T, Amano H, Bickerstaff A, Orosz CG, Novick AC, Tanabe K, Fairchild RL.

J Immunol. 2007 Oct 15;179(8):5238-45.

20.

Egr1: a novel target for ameliorating acute allograft rejection in an experimental lung transplant model.

Waki N, Yamane M, Yamamoto S, Okazaki M, Sugimoto S, Matsukawa A, Oto T, Miyoshi S.

Eur J Cardiothorac Surg. 2012 Mar;41(3):669-75. doi: 10.1093/ejcts/ezr030.

PMID:
22345187

Supplemental Content

Support Center